Literature DB >> 1944901

Epidemiology of progressive multifocal leukoencephalopathy in the United States: analysis of national mortality and AIDS surveillance data.

R C Holman1, R S Janssen, J W Buehler, M T Zelasky, W C Hooper.   

Abstract

We analyzed progressive multifocal leukoencephalopathy (PML) mortality data from 1979 to 1987 and data on persons with acquired immunodeficiency syndrome (AIDS) reported to the Centers for Disease Control (CDC). Based on analyses of multiple-cause-of-death vital statistics, deaths related to PML have increased fourfold from 1.5/10,000,000 persons in 1979 to 6.1/10,000,000 persons in 1987. The increase in the PML annual death rate began in 1984, occurred primarily in men 20 to 49 years of age, and was greatest in states known to have a high incidence of AIDS. In 1987, 56% of death certificates that listed PML as a cause of death also listed human immunodeficiency virus (HIV) infection. Analysis of AIDS case reports to the CDC from 1981 through June 1990 demonstrated that 0.72% of persons with AIDS were reported as having PML. Although most persons with AIDS who had PML were 20 to 49 years of age (84.6%), PML was reported more frequently among persons with AIDS greater than or equal to 50 years old than less than 50 years old. In addition, PML was reported more frequently among persons with AIDS who were exposed to HIV by blood transfusion than those in all other exposure categories. These data demonstrate that the increase in PML mortality from 1979 to 1987 was associated with the large increase in immunosuppressed persons with AIDS.

Entities:  

Mesh:

Year:  1991        PMID: 1944901     DOI: 10.1212/wnl.41.11.1733

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  30 in total

Review 1.  Epidemiological evidence and molecular basis of interactions between HIV and JC virus.

Authors:  J R Berger; A Chauhan; D Galey; A Nath
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

2.  Progressive Multifocal Leukoencephalopathy.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-07       Impact factor: 3.598

Review 3.  Assessing long-term drug safety: lessons (re) learned from raptiva.

Authors:  Nicole M Seminara; Joel M Gelfand
Journal:  Semin Cutan Med Surg       Date:  2010-03

Review 4.  Progressive multifocal leukoencephalopathy and newer biological agents.

Authors:  Joseph R Berger
Journal:  Drug Saf       Date:  2010-11-01       Impact factor: 5.606

Review 5.  Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.

Authors:  Chen S Tan; Igor J Koralnik
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

6.  A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy.

Authors:  Salim Chahin; Joseph R Berger
Journal:  J Neurovirol       Date:  2014-11-18       Impact factor: 2.643

7.  Age as a risk factor for early onset of natalizumab-related progressive multifocal leukoencephalopathy.

Authors:  Luca Prosperini; Cristina Scarpazza; Luisa Imberti; Cinzia Cordioli; Nicola De Rossi; Ruggero Capra
Journal:  J Neurovirol       Date:  2017-08-08       Impact factor: 2.643

Review 8.  Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps.

Authors:  Fariha Zaheer; Joseph R Berger
Journal:  Ther Adv Drug Saf       Date:  2012-10

9.  An animal model for progressive multifocal leukoencephalopathy.

Authors:  Sheila A Haley; Walter J Atwood
Journal:  J Clin Invest       Date:  2014-11-17       Impact factor: 14.808

10.  Unmasking of PML by HAART: unusual clinical features and the role of IRIS.

Authors:  Navdeesh Sidhu; J Allen McCutchan
Journal:  J Neuroimmunol       Date:  2009-12-04       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.